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Abstract
Aims Impaired left ventricular diastolic function leading to elevated left atrial pressures, particularly during exertion, is a key
driver of symptoms and outcomes in heart failure with preserved ejection fraction (HFpEF). Insertion of an interatrial shunt
device (IASD) to reduce left atrial pressure in HFpEF has been shown to be associated with short-term haemodynamic and
symptomatic beneﬁt. We aimed to investigate the potential effects of IASD placement on HFpEF survival and heart failure
hospitalization (HFH).
Methods and results Heart failure with preserved ejection fraction patients participating in the Reduce Elevated Left Atrial
Pressure in Patients with Heart Failure study (Corvia Medical) of an IASD were followed for a median duration of 739 days. The
theoretical impact of IASD implantation on HFpEF mortality was investigated by comparing the observed survival of the study
cohort with the survival predicted from baseline data using the Meta-analysis Global Group in Chronic Heart Failure heart
failure risk survival score. Baseline and post-IASD implant parameters associated with HFH were also investigated. Based upon
the individual baseline demographic and cardiovascular proﬁle of the study cohort, the Meta-analysis Global Group in Chronic
Heart Failure score-predicted mortality was 10.2/100 pt years. The observed mortality rate of the IASD-treated cohort was
3.4/100 pt years, representing a 33% lower rate (P = 0.02). By Kaplan–Meier analysis, the observed survival in IASD patients
was greater than predicted (P = 0.014). Baseline parameters were not predictive of future HFH events; however, poorer
exercise tolerance and a higher workload-corrected exercise pulmonary capillary wedge pressure at the 6 months post-IASD
study were associated with HFH.
Conclusions The current study suggests IASD implantation may be associated with a reduction in mortality in HFpEF.
Large-scale ongoing randomized studies are required to conﬁrm the potential beneﬁt of this therapy.
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Introduction
Heart failure with preserved ejection fraction (HFpEF) repre-
sents one of the most important contemporary challenges in
cardiovascular medicine. Prevalent HFpEF already accounts
for roughly half of the current heart failure (HF) burden,
and the incidence of HFpEF is increasing in the context of an
ageing population together with concomitant hypertension,
diabetes, and obesity.1–4 Patients with established HFpEF are
just as symptomatic as those with heart failure with reduced
ejection fraction (HFrEF).5,6 All-cause mortality in HFpEF is
substantially greater than that in age-matched healthy individ-
uals,7,8 approaching that observed in HFrEF patients.4 The
relative contribution of death due to non-cardiovascular
events in HFpEF is somewhat higher than in HFrEF.9,10
The pathophysiological basis of HFpEF is complex, includ-
ing both central and peripheral cardiovascular components
together with non-cardiovascular elements. In particular, im-
paired left ventricular diastolic function leading to elevated
left atrial (LA) pressure during physical activity is considered
a key driver of symptoms in HFpEF.11–14 Intrinsic LA
mechanical dysfunction may also contribute signiﬁcantly to
symptoms.15,16 To date, pharmacological interventions with
proven effectiveness in HFrEF have failed to achieve their
primary endpoints in HFpEF.17–20 Additionally, other recent
interventions directed at the nitric oxide–cyclic guanosine
monophosphate pathway have also proven ineffective.21–24
As further evidence of the central role of impaired diastolic
performance in HFpEF, it has been shown that poorer exer-
cise tolerance25 and survival 26 are associated with a more
rapid rise in pulmonary capillary wedge pressure (PCWP) dur-
ing exercise. Within this context, based on haemodynamic
simulations,27 an interatrial shunt device (IASD®, Corvia Med-
ical Inc., Tewksbury, MA, USA) was developed to reduce LA
pressure by allowing a modest amount of left-to-right
shunting in HFpEF patients.28,29 Open-label studies have sug-
gested a symptomatic and haemodynamic beneﬁt at 6 and
12 months,30,31 and a recent randomized trial demonstrated
haemodynamic beneﬁt compared with a sham control.32 To
date, however, the effect of this approach on heart failure
hospitalization (HFH) or survival remains unknown. Accord-
ingly, the objective of this study was to investigate the poten-
tial impact of IASD implantation on HFH and survival in the
intermediate term.
Methods
The Reduce Elevated Left Atrial Pressure in Patients with
Heart Failure (REDUCE LAP-HF) study was a multi-centre pro-
spective, non-randomized, open-label, single-arm study de-
signed to investigate the safety and performance of a novel
transcatheter IASD in 64 patients with symptoms of HF,
haemodynamic evidence of raised LA pressure (measured
as the PCWP) at rest or during supine bicycle exercise, and
a left ventricular ejection fraction (LVEF) > 40%. To
account, in part, for the potential effect differences in peak
workload and weight on PCWP, the exercise PCWP is also
presented as the ratio of PCWP to workload (W)/kg, that is,
PCWP/(W/kg) as previously reported.11,26 The study design,
patient demographics, and primary results have been
described in detail elsewhere.30,33 In brief, the average age
of the cohort was 70 years, and the majority (65%) were
women. Co-morbidities including hypertension, obesity,
diabetes, chronic obstructive pulmonary disease, and atrial
ﬁbrillation were common. Full exercise invasive haemody-
namic studies were conducted in 60 patients at 6 months
post-IASD implant.
The principle objective of the current study was to investi-
gate hard clinical outcomes in the REDUCE LAP-HF cohort
over the intermediate term. Exercise capacity, quality of life
(Minnesota Living with Heart Failure Score), and echocardiog-
raphy were optional assessments at 2 years. Haemodynamic
analyses were not conducted at this time point. All serious
adverse events were reported per protocol and adjudicated
by an independent clinical event committee. A second aim
was to investigate the relationship between the post-IASD
haemodynamic proﬁle (i.e. at 6 months) and HFH events.
Statistical methods
Normally distributed data are presented as mean ± standard
error of the mean and non-normal data as median and
25th–75th percentile range. Between-group comparisons
were performed using an unpaired Student’s t-test. Non-
parametric between-group comparisons were performed
using a Mann–Whitney U test. Repeated measures ANOVA
analysis of New York Heart Association (NYHA) status was
performed using Friedman’s test, with post hoc testing per-
formed using a Wilcoxon test.
To determine the theoretical impact of IASD implantation
on survival, we calculated 1 and 3 year predicted cohort out-
comes using the Meta-analysis Global Group in Chronic Heart
Failure (MAGGIC) prognostic model,34,35 a risk prediction tool
derived from a large (>40 000 patient group composed of
mixed clinical trial and observational cohorts) and validated
in a large real-world cohort of HF patients.36 The predicted
survival using the MAGGIC score was based on all relevant
patient and disease factors in the IASD cohort at baseline.
An exponential transformation was then applied to estimate
predicted survival for each 3 month time point between
baseline and 39 months. A comparison of predicted survival
with that observed following IASD treatment was performed
for the entire observation period balanced for key baseline
confounders such as LVEF and all other baseline MAGGIC
score variables. Observed and MAGGIC-predicted Kaplan–
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Meier survival curves were compared over the total follow-up
period and at 12, 24, and 36 months using log-rank test and
Z-tests. Similarly, validated scores for HFH in HFpEF patients
are not presently available. Hazard proportionality was
assessed via analysis of scaled Schoenfeld residuals. The null
hypothesis was rejected at P < 0.05. Statistical analyses were
conducted using SPSS version 22 (IBM, Armonk, NY, USA) or
Stata version 15 (StataCorp, College Station, TX, USA).
Statistical modelling of survival outcomes was conducted
independently by Synergus (Synergus AB, Stockholm, Sweden).
Results
Clinical event rates
Over the 3 year follow-up period, six study patients (9.4%)
died during the follow-up period, representing a mortality
rate of 3.4 deaths per 100 person-years (95% conﬁdence
interval 1.52–7.54) over a total observation period of
177.2 patient years. Of the six observed deaths, three were
adjudicated as being HF related, two were assessed not being
directly attributable to HF, and one occurred following a cere-
brovascular accident. Over the follow-up period, there were
42 HFH episodes occurring in 19 patients.
The observed all-cause mortality rate in IASD-treated
patients was signiﬁcantly lower than that predicted by the
MAGGIC score. The mortality rate predicted by the MAGGIC
score was 10.2/100 pt years (6.1–16.9). Taken together, this
observation represents a 33% lower mortality rate (hazard
ratio 0.67; 95% conﬁdence interval 0.09–0.89) relative to
the MAGGIC-predicted mortality across the full observation
period (P = 0.02). The corresponding Kaplan–Meier curves
are demonstrated in Figure 1, representing a greater survival
in IASD patients compared with MAGGIC-predicted out-
comes, P (log-rank) = 0.014. χ2 and P values for the log-rank
tests of observed vs. predicted mortality at 12, 24, and
36 months were, respectively, 2.96 (P = 0.085), 2.15
(P = 0.143), and 21.43 (P < 0.01).
Heart failure hospitalization and New York Heart
Association class
Over the follow-up period, 19 patients experienced an HFH
event, and the ﬁrst hospitalization event occurred at a me-
dian of 182 days. Of those with HFH events, nine patients ex-
perienced two or more HFH events. Survival was similar in
patients with an HFH event compared with those without
(three deaths per group, P = 0.31) albeit with small numbers.
As shown in Table 1, there were no signiﬁcant differences
in key baseline (pre-IASD) demographic, echocardiographic,
and haemodynamic features of patients according to subse-
quent HFH. Similarly, as shown in Figure 2, there were no
signiﬁcant differences in the baseline exercise intra-cardiac
pressures of patients categorized according to subsequent
HFH. Prior to IASD implantation, the peak exercise cardiac
index was similar in non-HFH vs. HFH patients: 4.3 ± 0.2 vs.
4.3 ± 0.3 L/min/m2. Six months after IASD implantation,
HFH patients had a lower 6 min walk distance and lower peak
exercise work capacity as shown in Table 2. The resting echo-
cardiographic and haemodynamic features were similar in
patients who experienced an HFH event (Table 2). Compari-
son of intra-cardiac pressures during exercise 6 months
after IASD implantation showed (Figure 3) that patients with
an HFH event had higher workload-corrected exercise
PCWP (94 ± 13 vs. 60 ± 5 mmHg/(W/kg), P = 0.021). The peak
Figure 1 Kaplan–Meier survival curves representing the observed and
predicted outcome for the heart failure with preserved ejection fraction
cohort.
Table 1 Baseline features according to HFH status
No HFH
(n = 45)
HFH
(n = 19) P value
Age (years) 69 ± 1 71 ± 2 0.37
Body mass index (kg/m2) 32 ± 1 34 ± 2 0.27
NT-proBNP (pg/mL) 332
(218–862)
595
(222–1790)
0.24
Atrial ﬁbrillation (%) 36 37 0.92
Hypertension (%) 80 84 0.69
IHD (%) 31 32 0.97
eGFR (mL/min/1.73 m2) 65 ± 3 54 ± 4 0.08
6MWD (m) 335 ± 16 316 ± 18 0.49
Peak exercise workload (W) 44 ± 3 40 ± 4 0.48
Echocardiography
LVEF (%) 47 ± 1 47 ± 1 0.66
LAVI (mL/m2) 34 ± 3 34 ± 3 0.88
RAVI (mL/m2) 35 ± 3 35 ± 3 0.95
TAPSE (cm) 2.0 ± 0.1 1.9 ± 0.1 0.52
Resting haemodynamics
RA pressure (mmHg) 9 ± 1 10 ± 1 0.15
PAm pressure (mmHg) 23 ± 1 25 ± 1 0.39
PCWP (mmHg) 17 ± 1 18 ± 1 0.40
Cardiac index (L/min/m2) 2.7 ± 0.1 2.7 ± 0.2 0.78
6MWD, 6 min walk distance; eGFR, estimated glomerular ﬁltration
rate; HFH, heart failure hospitalization; IHD, ischaemic heart dis-
ease; LAVI, left atrial volume index; LVEF, left ventricular ejection
fraction; NT-proBNP, N-terminal pro-brain natriuretic peptide;
PAm, mean pulmonary artery; PCWP, pulmonary capillary wedge
pressure; RA, right atrial; RAVI, right atrial volume index; TAPSE, tri-
cuspid annular plane systolic excursion.
Values are mean ± SEM or median (25th–75th percentile inter-
quartile range).
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exercise cardiac index was similar in non-HFH and HFH pa-
tients (5.2 ± 0.2 vs. 4.8 ± 0.3 L/min/m2).
At 2 years post-IASD implantation, there was a sustained
and signiﬁcant improvement in NYHA class compared with
baseline; however, there was a modest but signiﬁcant dimi-
nution in NYHA class compared with the 12 month time point
shown in Figure 4.
Discussion
Based upon evidence that impaired left ventricular diastolic
function and abnormal LA mechanical function contribute
substantially to the pathophysiology of HFpEF, our group
and others have investigated devices aimed at reducing
LA pressure by left-to-right atrial shunting through an iatro-
genic atrial septal passage.30,37 To date, sustained improve-
ments in quality of life, functional capacity, and exercise
haemodynamics have been observed in open-label IASD
studies extending out to 1 year post-implant.31 The recent
pilot double-blind, randomized trial demonstrated a signiﬁ-
cant reduction in exercise PCWP in IASD-treated HFpEF pa-
tients32 compared with sham control. The potential impact
of IASD placement on HFpEF mortality and HFH remains un-
known. Accordingly, the objective of this study was to ex-
amine the mortality and HFH rates in IASD-treated HFpEF
patients and to determine potential mechanisms by which
IASD placement may alter clinical outcomes.
In patients treated with an IASD in the open-label RE-
DUCE LAP-HF cohort, we observed a 33% lower mortality
rate than that predicted by the MAGGIC risk prediction
score over the entire observation period. The MAGGIC
score algorithm was derived from a meta-analysis of 30
clinical trials and observational studies of over 40 000 pa-
tients with HF across a range of LVEF, including those with
HFpEF and HFrEF, from which a risk prediction tool was
developed using 13 common parameters.35 A similar ap-
proach has previously been applied to assess the impact of
other interventions in HFrEF.38 The MAGGIC score estimated
Figure 2 Bar graphs represent baseline (pre-interatrial shunt device) peak exercise haemodynamic parameters in relation to subsequent heart failure
hospitalization (HFH) events. PA, pulmonary artery; PCWP, pulmonary capillary wedge pressure.
Table 2 Six month post-IASD features according to HFH status
No HFH
(n = 45)
HFH
(n = 19) P value
Body mass index (kg/m2) 32 ± 1 34 ± 2 0.28
NT-proBNP (pg/mL) 332
(180–821)
609
(304–2022)
0.09
eGFR (mL/min/1.73 m2) 63 ± 3 53 ± 4 0.08
6MWD (m) 375 ± 14 312 ± 23 0.03
Peak exercise workload (W) 52 ± 3 41 ± 5 0.048
Echocardiography
LVEF (%) 50 ± 1 47 ± 2 0.19
LAVI (mL/m2) 35 ± 4 35 ± 4 0.99
RAVI (mL/m2) 40 ± 4 40 ± 3 0.99
TAPSE (cm) 2.0 ± 0.1 1.9 ± 0.1 0.21
Resting haemodynamics
RA pressure (mmHg) 10 ± 1 12 ± 1 0.12
PAm pressure (mmHg) 24 ± 1 25 ± 1 0.49
PCWP (mmHg) 16 ± 1 18 ± 1 0.24
Cardiac index (L/min/m2) 3.4 ± 0.1 3.2 ± 0.2 0.37
6MWD, 6 min walk distance; eGFR, estimated glomerular ﬁltration
rate; HFH, heart failure hospitalization; LAVI, left atrial volume in-
dex; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal
pro-brain natriuretic peptide; PAm, mean pulmonary artery; PCWP,
pulmonary capillary wedge pressure; post-IASD, post-interatrial
shunt device; RA, right atrial; RAVI, right atrial volume index;
TAPSE, tricuspid annular plane systolic excursion.
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a substantially higher event rate, consistent with that re-
cently observed in the regional sub-analysis of the Treatment
of Preserved Cardiac Function Heart Failure with an Aldoste-
rone Antagonist study.39 The ability of the MAGGIC score to
reliably predict outcomes at 3 years was recently validated
in a large Swedish registry,36 although the study suggested
that the MAGGIC score may overestimate risk in lower risk
patients. However, the validation study had several limita-
tions, including multiple imputation procedures for missing
data and the combination of patients with LVEF > 50% and
those with an LVEF of 40–49%.36
Mortality events occurring in the present study were
predominantly cardiovascular, albeit in a small population.
The cause of death in patients with HFpEF has been some-
what unclear until recently. Meta-analyses of randomized
clinical trials together with observational studies and regis-
tries9,10 have shown that although the majority of deaths
are of a cardiovascular nature, the overall rate, mechanism,
and their proportion vary substantially. Speciﬁcally, whilst
progressive HF remains the commonest cause of cardiovas-
cular death, the contribution of other cardiovascular events
including sudden death, myocardial infarction, and stroke is
more variable.
The present study raises the possibility that a device-based
approach to reducing LA pressure may favourably affect
mortality in HFpEF patients. This observation is consistent
with two bodies of prior data. First, in a retrospective analy-
sis, Dorfs et al.26 showed that HFpEF patients with a more
marked exercise-mediated rise in PCWP had poorer survival
than those with lesser elevations. In conjunction, Adamson
et al.40 showed that HF therapy guided by an implanted
haemodynamic monitor in HFpEF patients was associated
with a lower HFH rate. Moreover, Zile et al.41 showed that a
3–5 mmHg reduction in estimated pulmonary artery diastolic
pressure was associated with lower mortality during a trial
of an implanted haemodynamic monitor, albeit in HFrEF
patients. The mechanism by which a reduction in LA ﬁlling
pressure might reduce mortality in HFpEF is unclear. Elevated
PCWP has been previously shown to drive cardiac sympa-
thetic outﬂow in HFrEF,42 which is implicated in the progres-
sion of HF and in the pathogenesis of arrhythmia.43
Figure 3 Bar graphs represent peak exercise haemodynamic parameters 6 months after interatrial shunt device (n = 60) implantation in relation to
subsequent heart failure hospitalization (HFH) events. PA, pulmonary artery; PCWP, pulmonary capillary wedge pressure.
Figure 4 Bar graph represents the New York Heart Association (NYHA)
class distribution of heart failure with preserved ejection fraction patients
prior to and after interatrial shunt device implantation. ***P < 0.001 vs.
baseline and +P < 0.05 vs. 12 months.
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Elevated natriuretic peptide levels have also been associ-
ated with a poorer outcome in HFpEF,44 which extends
the concept that elevated ﬁlling pressure per se may directly
contribute to outcome in HFpEF. Interestingly, whilst
angiotensin-converting enzyme inhibitors, angiotensin recep-
tor blockers, and aldosterone antagonists have not been
shown to improve survival overall in HFpEF, post hoc analy-
ses indicate that they may be effective in patients with rela-
tively lower natriuretic peptide levels.45 Whilst this may
appear counter-intuitive, the effect of these pharmacological
therapies on ﬁlling pressures in HFpEF has not been studied
in detail. A prior study by Kitzman et al.46 showed that
angiotensin-converting enzyme inhibition was without effect
on echocardiographic indices of diastolic function or left
ventricular ﬁlling pressures.
Heart failure hospitalization events are an important con-
tributor to the overall clinical burden associated with HFpEF.
Recent data indicate that cardiovascular precipitants are the
lead trigger for HFH in HFpEF patients.47 Speciﬁc causes
include arrhythmia, myocardial ischaemia, and dietary or
medication non-adherence. Common non-cardiovascular pre-
cipitants include infection and worsening renal function.
From the present study, patients with subsequent HFH events
tended to have worse renal function and higher N-terminal
pro-brain natriuretic peptide levels at baseline, although
these were not statistically signiﬁcant. Heart failure hospital-
ization patients had similar haemodynamics prior to IASD
implantation both at rest and during exercise. During
follow-up after IASD implantation, patients with a greater
6 month exercise capacity and a lower workload-corrected
peak PCWP had a lower likelihood of HFH. This observation
is consistent with the importance of pulmonary congestion
as a trigger for HFH.48 Importantly, we did not observe a
relationship between haemodynamic or echocardiographic
features of right heart volume overload, in the setting
of the IASD, with HFH. In the present study, patients
experiencing HFH events were not associated with subse-
quent increased mortality; however, the small sample size
prevents a deﬁnitive conclusion about the potential rela-
tionship between these events.
Limitations
The current data should be interpreted in the context of
several limitations. First, the study was an open-label study.
Second, although the predicted survival is consistent with
other reports in HFpEF patients, the use of the MAGGIC score
to derive a comparator survival curve may have generated
an overestimation of the true survival in a contemporaneous
group.39 Finally, whilst protocol-driven safety outcome
follow-up was available at up to 3 years, complete NYHA class
at 3 years was not available, and systematic echocardiogra-
phy was not required after 12 months.
Conclusions
Taken together, the current study is consistent with recent
data suggesting that both symptoms and outcomes are re-
lated to the magnitude of elevation of LA pressure in patients
with HFpEF. Our study also suggests that mitigation of LA
pressure elevation by deployment of an IASD may be associ-
ated with a reduction in mortality in HFpEF patients. Double-
blind randomized, sham procedure-controlled studies are
currently underway to further investigate the utility of this
therapeutic approach in HFpEF.
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